Grifols SA
corporate_fare Company Profile
Grifols SA (NASDAQ:GRFS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for GRFS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-28, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for GRFS spans 6-K, 20-F.
Recent high-impact activity:
- Grifols H1 2026: Revenue Climbs 2.6%, Net Profit Surges 28.7%, Refinancing Wraps Up
- Grifols Doses First Patients in Two Phase 3 Trials for Immunoglobulin Label Expansion
- Shareholders Approve Major Capital Reduction, Dividend, and Authorize Future Capital Actions
- Grifols Calls AGM to Vote on 10% Share Capital Reduction, 50% Capital Increase Authorization, and NASDAQ Listing
- Grifols Reports Strong Q1 2026 Results, Refinances Debt, and Explores US Biopharma IPO
Financial Snapshot
Short Interest & Short Volume
8.83 days to coverFINRA reported short interest of 3,414,455 shares in GRFS as of the September 15, 2026 settlement, a 0.1% decrease from the prior period — about 8.8 days to cover at its recent average daily volume. On October 2, 2026, 48.5% of GRFS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GRFS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.